JP7437490B2 - ヒトインテグリン（アルファ－４）（ベータ－７）の阻害 - Google Patents

ヒトインテグリン（アルファ－４）（ベータ－７）の阻害 Download PDF

Info

Publication number
JP7437490B2
JP7437490B2 JP2022509595A JP2022509595A JP7437490B2 JP 7437490 B2 JP7437490 B2 JP 7437490B2 JP 2022509595 A JP2022509595 A JP 2022509595A JP 2022509595 A JP2022509595 A JP 2022509595A JP 7437490 B2 JP7437490 B2 JP 7437490B2
Authority
JP
Japan
Prior art keywords
compound
substituted
certain embodiments
unsubstituted
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022509595A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542184A (ja
Inventor
バーサヴィッヒ，マシュー，ジー．
キュイ，ダン
ダウリング，ジェームズ，イー．
ハーン，クリストファー，エヌ．
ハリソン，ブライス，エー．
リン，フー－ヤン
リッパ，ブレイズ，エス．
ロジャーズ，ブルース，エヌ．
トロースト，ドーン，エム．
ゾン，チェン
コンズ，カイル，ディー．
ジェラシュート，アレクシー，アイ．
キム，ビュンチャン
ラフィ，サルマ
デイ，テイラー
ヒッキー，ユージーン
ハウアン，エヴェリン
ザラー，ロバート
Original Assignee
モーフィック セラピューティック，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モーフィック セラピューティック，インコーポレイテッド filed Critical モーフィック セラピューティック，インコーポレイテッド
Publication of JP2022542184A publication Critical patent/JP2022542184A/ja
Priority to JP2024018765A priority Critical patent/JP7717202B2/ja
Application granted granted Critical
Publication of JP7437490B2 publication Critical patent/JP7437490B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Radio Relay Systems (AREA)
  • Air Conditioning Control Device (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022509595A 2019-10-16 2020-10-16 ヒトインテグリン（アルファ－４）（ベータ－７）の阻害 Active JP7437490B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024018765A JP7717202B2 (ja) 2019-10-16 2024-02-09 ヒトインテグリン（アルファ－４）（ベータ－７）の阻害

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962916062P 2019-10-16 2019-10-16
US62/916,062 2019-10-16
PCT/US2020/056001 WO2021076902A1 (en) 2019-10-16 2020-10-16 INHIBITING HUMAN INTEGRIN α 4 β 7

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024018765A Division JP7717202B2 (ja) 2019-10-16 2024-02-09 ヒトインテグリン（アルファ－４）（ベータ－７）の阻害

Publications (2)

Publication Number Publication Date
JP2022542184A JP2022542184A (ja) 2022-09-29
JP7437490B2 true JP7437490B2 (ja) 2024-02-22

Family

ID=73198501

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2022509595A Active JP7437490B2 (ja) 2019-10-16 2020-10-16 ヒトインテグリン（アルファ－４）（ベータ－７）の阻害
JP2022523102A Active JP7437495B2 (ja) 2019-10-16 2020-10-16 ヒトインテグリンα４β７の阻害
JP2021576053A Active JP7209116B2 (ja) 2019-10-16 2021-10-15 ヒトインテグリンα４β７の阻害
JP2023000761A Active JP7500785B2 (ja) 2019-10-16 2023-01-06 ヒトインテグリンα４β７の阻害
JP2024018866A Active JP7702004B2 (ja) 2019-10-16 2024-02-09 ヒトインテグリンα４β７の阻害
JP2024018765A Active JP7717202B2 (ja) 2019-10-16 2024-02-09 ヒトインテグリン（アルファ－４）（ベータ－７）の阻害
JP2024091304A Pending JP2024116230A (ja) 2019-10-16 2024-06-05 ヒトインテグリンα４β７の阻害

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2022523102A Active JP7437495B2 (ja) 2019-10-16 2020-10-16 ヒトインテグリンα４β７の阻害
JP2021576053A Active JP7209116B2 (ja) 2019-10-16 2021-10-15 ヒトインテグリンα４β７の阻害
JP2023000761A Active JP7500785B2 (ja) 2019-10-16 2023-01-06 ヒトインテグリンα４β７の阻害
JP2024018866A Active JP7702004B2 (ja) 2019-10-16 2024-02-09 ヒトインテグリンα４β７の阻害
JP2024018765A Active JP7717202B2 (ja) 2019-10-16 2024-02-09 ヒトインテグリン（アルファ－４）（ベータ－７）の阻害
JP2024091304A Pending JP2024116230A (ja) 2019-10-16 2024-06-05 ヒトインテグリンα４β７の阻害

Country Status (37)

Country Link
US (3) US11104661B1 (https=)
EP (3) EP4045039B1 (https=)
JP (7) JP7437490B2 (https=)
KR (2) KR20220102669A (https=)
CN (3) CN119192137A (https=)
AR (1) AR120244A1 (https=)
AU (2) AU2020366435A1 (https=)
BR (1) BR112022007284A2 (https=)
CA (1) CA3154269A1 (https=)
CL (1) CL2022000959A1 (https=)
CO (1) CO2022005759A2 (https=)
CR (1) CR20220205A (https=)
CU (1) CU20220027A7 (https=)
DK (1) DK4045039T3 (https=)
DO (2) DOP2022000081A (https=)
EC (1) ECSP22038978A (https=)
ES (1) ES3035561T3 (https=)
FI (1) FI4045039T3 (https=)
HR (1) HRP20250749T1 (https=)
HU (1) HUE071814T2 (https=)
IL (2) IL319053A (https=)
LT (1) LT4045039T (https=)
MA (1) MA57399B1 (https=)
MD (1) MD4045039T2 (https=)
MX (1) MX2022004406A (https=)
PE (1) PE20221829A1 (https=)
PH (1) PH12022550886A1 (https=)
PL (1) PL4045039T3 (https=)
PT (1) PT4045039T (https=)
PY (1) PY2065718A (https=)
RS (1) RS66976B1 (https=)
SI (1) SI4045039T1 (https=)
TW (7) TWI775182B (https=)
UA (1) UA130059C2 (https=)
UY (1) UY38926A (https=)
WO (3) WO2021076902A1 (https=)
ZA (2) ZA202203872B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773573B1 (en) 2018-04-12 2026-03-18 Morphic Therapeutic, Inc. Antagonists of human integrin (alpha4)(beta7)
FI3873884T3 (fi) 2018-10-30 2025-02-24 Gilead Sciences Inc 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa
WO2020232256A1 (en) 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
TWI775182B (zh) 2019-10-16 2022-08-21 美商莫菲克醫療股份有限公司 抑制人類整合素αβ
ES3064674T3 (en) 2019-10-16 2026-04-28 Chemocentryx Inc Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
JP7736678B2 (ja) 2019-10-16 2025-09-09 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド
US20250195485A1 (en) * 2021-12-27 2025-06-19 Xizang Haisco Pharmaceutical Co., Ltd. Propionic acid derivative and medical use thereof
KR20250061759A (ko) 2022-09-09 2025-05-08 시젱 하이스코 파마수티칼 씨오., 엘티디. 프로피온산 유도체 및 이의 의약에서의 응용
JP2025542171A (ja) 2022-12-22 2025-12-25 シンセラ， インコーポレイテッド アルファ４ベータ７インテグリンアンタゴニスト及びその使用
AU2024226489A1 (en) * 2023-02-21 2025-10-02 C4X Discovery Limited Macrocyclic alpha4beta7 integrin inhibitors
CN121335980A (zh) 2023-05-26 2026-01-13 阿达尔克斯制药有限公司 Sod1调节组合物及其使用方法
TW202508571A (zh) 2023-07-28 2025-03-01 大陸商上海翰森生物醫藥科技有限公司 一種苯并含氮雜環類衍生物調節劑、其製備方法和應用
WO2025026955A1 (en) * 2023-07-28 2025-02-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2025176107A1 (zh) * 2024-02-20 2025-08-28 西藏海思科制药有限公司 一种吡啶酮衍生物及其在医药上的应用
CN118702712B (zh) * 2024-07-04 2025-11-11 安徽普利药业有限公司 一种n-(3-苯10硼酸)-l-天冬氨酸中间体制备方法
WO2026018017A1 (en) * 2024-07-19 2026-01-22 C4X Discovery Limited Therapeutic compounds
WO2026018016A1 (en) * 2024-07-19 2026-01-22 C4X Discovery Limited Therapeutic compounds
CN119504796B (zh) * 2024-11-20 2026-03-10 南通大学附属医院 一种具有抗肿瘤活性的化合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021531234A (ja) 2018-04-12 2021-11-18 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリンα４β７のアンタゴニスト
JP2023500437A (ja) 2019-10-16 2023-01-06 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリンα４β７の阻害

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU681396B2 (en) 1993-03-31 1997-08-28 G.D. Searle & Co. 1-amidinophenyl-pyrrolidones piperidinones azetinones as platelet aggregation inhibitors
DE4427979A1 (de) 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
CA2268270A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Heterocyclic derivatives as factor xa inhibitors
WO1998016547A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
AU751950B2 (en) * 1997-11-24 2002-09-05 Merck & Co., Inc. Substituted beta-alanine derivatives as cell adhesion inhibitors
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
AU4584199A (en) 1998-06-29 2000-01-17 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
WO2000006169A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
GB9826174D0 (en) * 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
RU2255933C9 (ru) 1999-05-07 2005-11-20 Тексэс Байотекнолоджи Копэрейшн ПРОИЗВОДНЫЕ ПРОПИОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СЕЛЕКТИВНОГО ИНГИБИРОВАНИЯ СВЯЗЫВАНИЯ α4β1 ИНТЕГРИНА
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
ES2288871T3 (es) 1999-09-24 2008-02-01 Genentech, Inc. Derivados de tirosina.
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
JP2004510708A (ja) * 2000-08-30 2004-04-08 ファルマシア・コーポレーション ＧＥＭ置換αｖβ３インテグリンアンタゴニスト
DE10111876A1 (de) 2001-03-10 2002-09-19 Aventis Pharma Gmbh Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe
DE10154280A1 (de) 2001-11-05 2003-05-15 Wilex Ag Antagonisten für alpha¶4¶-Integrine
DK1485127T3 (da) 2002-02-25 2011-10-03 Elan Pharm Inc Anvendelse af midler til behandling af inflammation
WO2006026759A2 (en) 2004-09-03 2006-03-09 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
EP1863940B1 (en) 2005-03-03 2012-06-06 Seedlings Life Science Ventures, LLC. Method of risk management for patients undergoing natalizumab treatment
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
EA013080B1 (ru) 2005-06-09 2010-02-26 Юсб Фарма С.А. 2,6-хинолинильные производные, способы их получения и их применение
US20070207141A1 (en) 2006-02-28 2007-09-06 Ivan Lieberburg Methods of treating inflammatory and autoimmune diseases with natalizumab
US20100272680A1 (en) 2009-02-09 2010-10-28 Subramanian Baskaran Piperidinyl Cyclic Amido Antiviral Agents
RU2016127812A (ru) 2011-03-31 2018-12-06 Дженентек, Инк. Способы введения антагонистов интегрина бета7
PL2903691T3 (pl) 2012-10-05 2019-10-31 Hoffmann La Roche Sposoby diagnozowania i leczenia nieswoistego zapalenia jelit
WO2015148809A1 (en) 2014-03-27 2015-10-01 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
WO2016011940A1 (zh) 2014-07-25 2016-01-28 江苏恒瑞医药股份有限公司 氮茚-酰胺类衍生物、其制备方法及其在医药上的应用
WO2016086147A1 (en) * 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
HK1244229A1 (zh) 2015-02-26 2018-08-03 F. Hoffmann-La Roche Ag 治疗CROHN病的整联蛋白β7拮抗剂和方法
MX394210B (es) * 2017-02-28 2025-03-04 Morphic Therapeutic Inc INHIBIDORES DE INTEGRINA AVß6.
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US10246451B2 (en) 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
JP7189368B2 (ja) * 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
FI3873884T3 (fi) 2018-10-30 2025-02-24 Gilead Sciences Inc 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa
EP3873605B1 (en) 2018-10-30 2024-10-23 Gilead Sciences, Inc. Compounds for inhibition of alpha4beta7 integrin
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021531234A (ja) 2018-04-12 2021-11-18 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリンα４β７のアンタゴニスト
JP2023500437A (ja) 2019-10-16 2023-01-06 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリンα４β７の阻害

Also Published As

Publication number Publication date
IL292296A (en) 2022-06-01
CL2022000959A1 (es) 2023-04-28
WO2021076890A4 (en) 2021-06-10
FI4045039T3 (fi) 2025-06-20
JP7702004B2 (ja) 2025-07-02
US20240174632A1 (en) 2024-05-30
MX2022004406A (es) 2022-08-25
LT4045039T (lt) 2025-08-11
JP7437495B2 (ja) 2024-02-22
SI4045039T1 (sl) 2025-07-31
WO2022081983A1 (en) 2022-04-21
JP2024116230A (ja) 2024-08-27
DK4045039T3 (da) 2025-06-30
EP4045039A1 (en) 2022-08-24
DOP2022000081A (es) 2022-07-31
PY2065718A (es) 2023-01-17
BR112022007284A2 (pt) 2022-07-05
CN115087444B (zh) 2024-09-17
TWI840047B (zh) 2024-04-21
TW202500558A (zh) 2025-01-01
TWI775182B (zh) 2022-08-21
ES3035561T3 (en) 2025-09-04
JP2022548809A (ja) 2022-11-22
TWI802477B (zh) 2023-05-11
UA130059C2 (uk) 2025-10-29
EP4045039B1 (en) 2025-04-23
TW202126624A (zh) 2021-07-16
JP2023500437A (ja) 2023-01-06
IL319053A (en) 2025-04-01
IL292296B1 (en) 2025-03-01
MA57399B1 (fr) 2025-06-30
TW202244040A (zh) 2022-11-16
JP7717202B2 (ja) 2025-08-01
EP4045039A4 (en) 2023-12-13
DOP2025000034A (es) 2025-04-08
TWI791304B (zh) 2023-02-01
CN116783161A (zh) 2023-09-19
KR20220102669A (ko) 2022-07-20
PH12022550886A1 (en) 2023-05-03
WO2021076902A1 (en) 2021-04-22
ZA202303992B (en) 2024-06-26
CN119192137A (zh) 2024-12-27
JP2024054296A (ja) 2024-04-16
EP4228634A4 (en) 2024-12-18
JP7500785B2 (ja) 2024-06-17
HUE071814T2 (hu) 2025-09-28
TW202500559A (zh) 2025-01-01
EP4559525A3 (en) 2025-08-20
TWI888065B (zh) 2025-06-21
JP7209116B2 (ja) 2023-01-19
US11104661B1 (en) 2021-08-31
HRP20250749T1 (hr) 2025-08-15
CU20220027A7 (es) 2022-12-12
ECSP22038978A (es) 2022-06-30
AR120244A1 (es) 2022-02-09
TW202332675A (zh) 2023-08-16
ZA202203872B (en) 2024-01-31
CN115087444A (zh) 2022-09-20
TWI900200B (zh) 2025-10-01
WO2021076890A1 (en) 2021-04-22
EP4559525A2 (en) 2025-05-28
CN116783161B (zh) 2026-04-03
CA3154269A1 (en) 2021-04-22
UY38926A (es) 2021-05-31
AU2021361031A1 (en) 2023-06-08
JP2024054293A (ja) 2024-04-16
TW202222793A (zh) 2022-06-16
TWI857592B (zh) 2024-10-01
AU2020366435A1 (en) 2022-04-21
JP2023036958A (ja) 2023-03-14
MD4045039T2 (ro) 2025-11-30
RS66976B1 (sr) 2025-07-31
US11370773B1 (en) 2022-06-28
PT4045039T (pt) 2025-07-02
EP4228634A1 (en) 2023-08-23
CR20220205A (es) 2022-07-22
JP2022542184A (ja) 2022-09-29
PL4045039T3 (pl) 2025-09-15
KR20230088376A (ko) 2023-06-19
TW202315868A (zh) 2023-04-16
CO2022005759A2 (es) 2022-05-20
IL292296B2 (en) 2025-07-01
PE20221829A1 (es) 2022-11-29

Similar Documents

Publication Publication Date Title
JP7437490B2 (ja) ヒトインテグリン（アルファ－４）（ベータ－７）の阻害
TW202123942A (zh) Ｂｒｄ９雙官能基降解劑及其使用方法
CN112312910A (zh) 人整合素α4β7拮抗剂
KR20020069362A (ko) 함질소환 화합물 및 이들을 포함하는 의약 조성물
JP7051009B2 (ja) アミノペプチダーゼａ阻害剤及びそれを含む医薬組成物
EA052724B1 (ru) ИНГИБИРОВАНИЕ ИНТЕГРИНА ЧЕЛОВЕКА α4β7
TW201736341A (zh) 丙啶磺醯胺類化合物及其使用方法
OA21139A (en) Inhibiting human integrin ALPHA4BETA7.
KR20020095418A (ko) Ｖｌａ-4 억제제 화합물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220303

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220303

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220303

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220413

A25B Request for examination refused [due to the absence of examination request for another application deemed to be identical]

Free format text: JAPANESE INTERMEDIATE CODE: A2522

Effective date: 20220913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230719

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240209

R150 Certificate of patent or registration of utility model

Ref document number: 7437490

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02